Alza, Cygnus drug delivery news
The U.S. Court of Appeals for the Federal Circuit upheld a 1995 decision that dismissed a lawsuit filed by CYGN. The suit alleged violation of U.S. antitrust laws and sought a declaration of unenforceability and invalidity of AZA's U.S. Patent No. 4,588,580 covering fentanyl transdermal patches. Fentanyl is an analgesic for post-operative pain and chronic pain. The appeals court reiterated the earlier decision, stating that CYGN failed to establish the presence of an actual controversy between the parties.
CYGN hasn't determined its response. Spokesperson Craig Carlson said the company had not been investing in its fentanyl program due to the lawsuits, and the analysts who follow the company do not include fentanyl revenues in their models. ...